Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.55 and has seen 0.43 million shares traded in the recent trading session. The company, currently valued at $287.06M, closed the recent trade at $4.32 per share which meant it gained $0.2 on the day or 4.73% during that session. The CRDF stock price is -30.56% off its 52-week high price of $5.64 and 53.47% above the 52-week low of $2.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.36 million shares traded. The 3-month trading volume is 1.13 million shares.
The consensus among analysts is that Cardiff Oncology Inc (CRDF) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Sporting 4.73% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CRDF stock price touched $4.32 or saw a fall of -1.65%. Year-to-date, Cardiff Oncology Inc shares have moved 71.91%, while the 5-day performance has seen it change 5.76%. Over the past 30 days, the shares of Cardiff Oncology Inc (NASDAQ:CRDF) have changed 13.25%. Short interest in the company has seen 17.29 million shares shorted with days to cover at 17.21.
Cardiff Oncology Inc (CRDF) estimates and forecasts
The company’s shares have gained 24.35% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.36% over the past 5 years. Earnings growth for 2025 is a modest 16.32% while over the next 5 years, the company’s earnings are expected to decrease by -7.49%.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders own 5.64% of the company shares, while shares held by institutions stand at 45.29% with a share float percentage of 47.99%. Investors are also buoyed by the number of investors in a company, with Cardiff Oncology Inc having a total of 144.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 2.63 million shares worth more than $5.84 million. As of 2024-06-30, BLACKROCK INC. held 5.8637% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 2.14 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.74 million and represent 4.766% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 2.29% shares in the company for having 1.52 shares of worth $6.58 million while later fund manager owns 1.47 shares of worth $6.35 million as of May 31, 2025 , which makes it owner of about 2.21% of company’s outstanding stock.
